DEFA14A: Adverum Biotechnologies Amends Non-Employee Director Compensation Policy

Adverum Biotechnologies updates its non-employee director compensation policy, adjusting cash and equity compensation based on the company's market capitalization.

Summary

• Adverum Biotechnologies has amended and restated its non-employee director compensation policy, effective May 22, 2024.
• The updated policy includes adjustments to total direct annual compensation based on the company's market capitalization.
• When the company's market capitalization is below $250 million, total direct annual compensation will not exceed $150,000.
• If the market capitalization is between $250 million and $500 million, compensation will not exceed $250,000.
• For market capitalization between $500 million and $1 billion, compensation is capped at $400,000.
• If the market capitalization exceeds $1 billion, compensation will not exceed $475,000.
• Non-employee directors will receive annual retainers for board and committee service, with additional retainers for chairs.
• Initial equity grants to new non-employee directors will have an option value of 200% of the most recent annual director option.
• Annual equity grants to existing non-employee directors will be based on the median annual equity award granted to non-employee directors of the company's peer group.
• The chair of the board will receive an additional equity grant equal to 30% of the annual director option value.
• Options will vest annually, with accelerated vesting upon a change in control.

Sentiment

Score: 7

Explanation: The document outlines a standard corporate governance update regarding director compensation. The sentiment is neutral to slightly positive as it reflects a structured approach to attracting and retaining qualified board members.

Positives

• The updated compensation policy provides a structured approach to compensating non-employee directors based on the company's market capitalization.
• The policy includes both cash and equity compensation, aligning director interests with shareholder value.
• The accelerated vesting of options upon a change in control provides an incentive for directors to support strategic transactions.

Risks

• The compensation limits may need to be revisited if the company's market capitalization significantly changes.
• The reliance on peer group data for annual equity grants could lead to compensation levels that are not aligned with the company's performance.

Future Outlook

The compensation policy will remain in effect until revised or rescinded by the Board or the Compensation Committee, with the compensation limits applying for a period of three years.

Industry Context

Companies regularly review and update their director compensation policies to remain competitive and attract qualified board members. This update aligns Adverum's compensation with its current market capitalization and peer group practices.

Comparison to Industry Standards

• Director compensation typically includes a mix of cash retainers and equity grants.
• Cash retainers are often differentiated based on board and committee roles, with chairs receiving higher compensation.
• Equity grants are intended to align director interests with shareholder value and are often benchmarked against peer companies.
• Comparable companies in the biotechnology industry include companies such as BioMarin Pharmaceutical, Sarepta Therapeutics, and Alnylam Pharmaceuticals, which also utilize a mix of cash and equity compensation for their non-employee directors.

Corporate Governance

Stakeholder Impact

• Shareholders: The updated compensation policy aims to align director interests with shareholder value.
• Non-Employee Directors: The policy outlines the cash and equity compensation they will receive for their service.
• Employees: The policy does not directly impact employees, but a well-compensated and effective board can contribute to the company's overall success.

Next Steps

• The amended compensation policy will be implemented immediately.
• The company will continue to monitor its market capitalization and peer group data to ensure the compensation policy remains competitive.
• Stockholders will vote on relevant proposals at the Annual Meeting on June 17, 2024.

Key Dates

Keywords

compensation, non-employee director, equity, retainer, market capitalization, Adverum Biotechnologies